Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Research & Development (2021 - 2025)

Senti Biosciences has reported Research & Development over the past 5 years, most recently at $7.8 million for Q4 2025.

  • Quarterly results put Research & Development at $7.8 million for Q4 2025, changed 0.15% from a year ago — trailing twelve months through Dec 2025 was $37.6 million (up 9.4% YoY), and the annual figure for FY2025 was $37.6 million, up 9.4%.
  • Research & Development for Q4 2025 was $7.8 million at Senti Biosciences, down from $10.5 million in the prior quarter.
  • Over the last five years, Research & Development for SNTI hit a ceiling of $10.5 million in Q3 2025 and a floor of $5.2 million in Q2 2021.
  • Median Research & Development over the past 5 years was $7.8 million (2024), compared with a mean of $8.0 million.
  • Biggest five-year swings in Research & Development: surged 76.64% in 2022 and later decreased 25.64% in 2023.
  • Senti Biosciences' Research & Development stood at $6.4 million in 2021, then increased by 9.8% to $7.0 million in 2022, then grew by 29.63% to $9.1 million in 2023, then dropped by 14.8% to $7.8 million in 2024, then fell by 0.15% to $7.8 million in 2025.
  • The last three reported values for Research & Development were $7.8 million (Q4 2025), $10.5 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.